Thanks RBx.
This may not be exactly apples for apples, but in relation to your first point above, if therapy with Veyonda outperforms Dexamethasone (attached link), then one might assume that the FDA would be extremely interested in approving trials in the US.
From the report:
After 28 days, 33% of the steroid-treated patients had died, compared to 41% of the patients on usual care or a placebo. In the meta-analysis, the difference in absolute mortality translated into a 34% reduction in the risk of death for those given steroids — a statistically significant result.
From a shareholder viewpoint, if we get efficacy similar to LuPIN, then surely Veyonda becomes head and shoulders the Gold standard.
Inexpensive steroids reduce deaths of hospitalized COVID 19 patients
Add to My Watchlist
What is My Watchlist?
